ASC2ESCALATE (CABL001AUS08) = Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia [USA]

Study title

ASC2ESCALATE = Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Scientific title

A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase – Chronic Myelogenous Leukemia

Type of study

Trial after therapy failure or intolerance



Current status


Other trial ID

CABL001AUS08; NCT05384587

What is the purpose of the study

This is a study to evaluate oral asciminib in patients with CML in chronic phase (CP) who have been previously treated with one prior ATP- binding site tyrosine kinase inhibitor (TKI) with discontinuation due to treatment failure, warning or intolerance  [second line (2L) patient cohort].

This study also gains insights into the effect of asciminib when used in first line (1L) treatment. To this end, newly diagnosed CML-CP patients who may have received a TKI for up to 4 weeks are included in a separate 1L patient cohort.

What will happen during the study

This trial consists of three periods: screening and baseline for up to 28 days, treatment with ascimib for up to 104 weeks and a safety follow up period for 30 days.

Patients with CML-CP without T315I mutation who had received 1 prior ATP-binding site TKI will be considered for inclusion in the 2L patient cohort of this trial.

In addition, newly diagnosed CML-CP patients will be considered for inclusion in a separate 1L patient cohort.

All eligible patients will initially receive asciminib 80 mg once daily. At 6 months of study treatment, patients who have achieved BCR-ABL1IS ≤1% will continue on the same dose whereas those who have not achieved this will increase their dose to 200 mg once daily.

At 12 months of study treatment, patients will be evaluated for the primary endpoint of the study (MMR at 12 month in 2L patient cohort). They will then:


  • continue on the current dose of asciminib if MMR is achieved, or
  • increase dose to 200 mg once daily if they are on 80 mg once daily dosing and have not achieved MMR, or
  • increase dose to 200 mg twice daily if they are on 200 mg once daily dosing and have not achieved MMR, or
  • be taken off the study and switched to Investigator’s agent of choice if MMR is not achieved and it is in the interest of the patient based on investigator’s clinical judgment.

Key inclusion criteria

This study includes patients of all sexes who:

  • are aged 18 years or older
  • have chronic myelogenous leukemia in chronic phase (CML-CP), no previous accelerated phase (AP) or blast crisis (BC)
  • have an Eastern Co-Operative Group (ECOG) status of 0, 1 or 2
  • have adequate end organ function within 14 days before the first dose of asciminib treatment.

Further criteria apply. Please discuss these with your doctor or study staff.

Key exclusion criteria

This study does not include patients who:

  • have been treated
    – with 2 or more ATP-binding site TKIs (for second line patient cohort)
    – more than 4 weeks with 1-ATP-binding site TKIs (for first line patient cohort)
  • have been treated previously with asciminib
  • have known presence of a T315I mutation at any time before study entry
  • have a known second chronic phase of CML after previous progression to AP/BC.

Further criteria apply. Please discuss these with your doctor or study staff.

Estimated primary completion date

February 2026

Where can I find additional information

You can find a study description in the US registry This is a database provided by the U. S. National Institutes of Health.

Study sponsor

Novartis Pharmaceuticals

Scientific lead / contact

Novartis Pharmaceuticals

Principal investigator

Novartis Pharmaceuticals

Study centers / principal investigators

United States


University of Alabama at Birmingham
Birmingham, Alabama, 35233-0271
Principal Investigator: Omer Jamy


Alaska Oncology and Hematology
Anchorage, Alaska, 99508
Principal Investigator: Steven Liu


City Hope of Phoenix
Scottsdale, Arizona, 85258
Principal Investigator: Jeffrey Schriber

USO Arizona Oncology
Tucson, Arizona, 85711
Principal Investigator: Manda Sudhir


Onco Inst of Hope and Innovation
Cerritos, California, 90703
Principal Investigator: Arati Rani Chand

City of Hope National Medical
Duarte, California, 91010
Principal Investigator: Paul Koller

UCSF Fresno Internal Medicine
Fresno, California, 93701
Principal Investigator: Haifaa Abdulhaq

Virginia K Crosson Cancer Center
Fullerton, California, 92835
Principal Investigator: Steven Kim

Los Angeles, California, 90095
Principal Investigator: Gary Schiller

Lundquist Inst BioMed at Harbor
Torrance, California, 90509-2910
Principal Investigator: Sarah Tomassetti


Rocky Mountain Cancer Centers USOR
Bolder, Colorado, 80304
Principal Investigator: David J. Andorsky


The Stamford Hospital
Stamford, Connecticut, 06904
Principal Investigator: Kelsey Sokol


Florida Cancer Specialists
Fort Myers, Florida, 33901
Principal Investigator: Blessy Jacob

Baptist MD Anderson Cancer Center
Jacksonville, Florida, 32207
Principal Investigator: Maxim Norkin

Florida Cancer Specialists North
Saint Petersburg, Florida, 33705
Principal Investigator: Gustavo Alfonso Fonseca

Florida Cancer Specialists East
Stuart, Florida, 34994
Principal Investigator: Shachar Peles


City of Hope Atlanta
Atlanta, Georgia, 30033
Principal Investigator: Sabarish Ayyappan

Emory University School of Medicine/Winship Cancer Institute
Atlanta, Georgia, 30308
Principal Investigator: Anthony Michael Hunter

Augusta University Georgia
Augusta, Georgia, 30912
Principal Investigator: Jorge Cortes

Northwest Georgia Oncology Center
Marietta, Georgia, 30060
Principal Investigator: Steve McCune


Franciscan Health Indianapolis
Indianapolis, Indiana, 42637
Principal Investigator: Brian Mulherin


Wichita Community CIcI Onco Program Oncology
Wichita, Kansas, 67214
Principal Investigator: Shaker R Dakhil


University of Kentucky
Lexington, Kentucky, 40536
Principal Investigator: Reinhold Munker


Louisiana State University Main Centre
Shreveport, Louisiana, 71130
Principal Investigator: Poornima Ramadas


Dana Farber Cancer Center
Boston, Massachusetts, 02215
Principal Investigator: Marlise Luskin


Jackson Onc Associates
Jackson, Mississippi, 39216
Principal Investigator: Thomas Williamson


University Missouri Ellis Fischel Cancer Center
Columbia, Missouri, 65203
Principal Investigator: Hildebrandt Gerhard

Siteman Cancer Center
Saint Louis, Missouri, 63110
Principal Investigator: Camille N Abboud


St Vincent Frontier Cancer Center
Billings, Montana, 59102
Principal Investigator: Patrick Cobb


Nebraska Hematology-Oncology, P.C.
Lincoln, Nebraska, 68506
Principal Investigator: Kailash Mosalpuria

New Hampshire

Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Principal Investigator: Swaroopa Yerrabothala

New Jersey

Care Access Research Clifton
Clifton, New Jersey, 07013
Principal Investigator: Richards Afjonja

Hackensack Meridian Health Research
Brick, New Jersey, 88837
Principal Investigator: Evan Naylor

Hackensack University Medical Ctr
Hackensack, New Jersey, 07601
Principal Investigator: James McCloskey

Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
Principal Investigator: Dale Schaar

New Mexico

Albuquerque, New Mexico, 87102
Principal Investigator: Charles Foucar

New York

Clinical Research Alliance Research
Lake Success, New York, 11042
Principal Investigator: James D Olimpio

NYU Langone Long Island
Mineola, New York, 11501
Principal Investigator: Kiner-Strachan Bonnie

Manhattan Hematol Oncol Associates
New York, New York, 10016
Principal Investigator: Alec Goldenberg

New York Bld And Cancer Specialists
Port Jefferson, New York, 11776
Principal Investigator: Richard Zuniga

SUNY Stony Brook Medical Oncology
Stony Brook, New York, 11794-8174
Principal Investigator: Michael A Schuster

SUNY Upstate Medical Center
Syracuse, New York, 13210
Principal Investigator: Teresa C Gentile

North Carolina

University of North Carolina Hospital
Chapel Hill, North Carolina,  27514
Principal Investigator: Josh Zeidner

Novant Health Heart and Vascular Institute
Charlotte, North Carolina, 28204
Principal Investigator: James Dugan

Duke University Medical Center
Durham, North Carolina, 27710
Principal Investigator: Lindsay Rein

Wake Forest University Health Sciences Oncology
Winston-Salem, North Carolina, 27157
Principal Investigator: Bayard L. Powell


Hematology Oncology Care
Cincinnati, Ohio, 45236
Principal Investigator: Kruti Patel


Oregon Health and Sciences University
Portland, Oregon, 97239
Principal Investigator: Michael Charles Heinrich


Thomas Jefferson University
Philadelphia, Pennsylvania, 19107
Principal Investigator: Lindsay Wilde

South Carolina

Bon Secours Caner Center
Greenville, South Carolina, 29607
Principal Investigator: Robert David Siegel

South Dakota

Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Principal Investigator: Xavier Andrade-Gonzalez


Texas Oncology, P.A.
Austin, Texas, 78121
Principal Investigator:Jason M. Melear

Texas Oncology TX Oncology Baylor
Dallas, Texas, 752521
Principal Investigator: Moshe Yair Levy

Ctr for Cancer and Blood Disorders
Forth Worth, Texas, 76104
Principal Investigator: Latha Polavaram

Houston Methodist Hospital
Houston, Texas, 77030
Principal Investigator: Shilpan Shah

University of TX MD Anderson Cancer Center
Houston, Texas, 77030
Principal Investigator: Koji Sasaki

Mays Cancer Center
San Antonio, Texas, 78229
Principal Investigator: Zohra Nooruddin

Texas Oncology San Antonio TO San Antonio
San Antonio, Texas, 78258
Principal Investigator: John Renshaw

Texas Oncology Northeast Texas
Tyler, Texas, 75702
Principal Investigator: Habte Yimer


Community Cancer Trials of Utah
Ogden, Utah, 84405
Principal Investigator: Carl Gray

Huntsman Cancer Institute
Salt Lake City, Utah, 84112
Principal Investigator: Srinivas Tantravahi


Virginia Cancer Specialists
Gainesville, Virginia, 20155
Principal Investigator: Mitul Gandhi

Virginia Oncology Associates VOA – Lake Wright
Norfolk, Virginia, 23502
Principal Investigator: Robert Richard


VA Puget Sound Health Care System
Seattle, Wisconsin, 98108
Principal Investigator: Ehab Atallah

Fred Hutch Cancer Research
Seattle, Washington, 98109
Principal Investigator: Vivian Oehler

Northwest Medical Specialties
Tacoma, Washington, 98405
Principal Investigator: Frank Senecal


Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Principal Investigator: Ehab Atallah